Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes.
This study aimed to clarify the controversial effects of acute and short-term salbutamol (SAL) intake on sprint performance in healthy athletes. Based on the results of previous studies, an anabolic effect for the short-term treatment and increased glycolysis in both treatments were hypothesized. Eight male recreational athletes completed force-velocity exercise tests after administration of placebo (gelatin), acute oral SAL (6 mg) or short-term oral SAL (12 mg day(-1) for 3 weeks), using a double-blind and randomized protocol. A friction-loaded cycle ergometer fitted with a strain gauge, and an incremental encoder ensured accurate measurement of the force-velocity relationship during sprints. Mechanical data were averaged during each pedal downstroke. Compared with placebo after both acute and 3 weeks of continuous treatment, the force-velocity relationship shifted to the right with power output gains of 14 and 8% (p < 0.001), respectively. This effect was less marked for 3 weeks of continuous treatment compared with acute administration (p < 0.001), suggesting a down-regulation in adrenoceptors. Our first hypothesis thus seems rejected. Significantly higher end-of-exercise and recovery blood lactate concentrations were found under SAL compared with placebo (p < 0.001), supporting our second hypothesis. In conclusion, these data indicate that oral administration of SAL is an effective ergogenic aid for sprint exercise in non-asthmatic athletes. Moreover, an acute treatment seems to be more effective than 3 weeks of continuous treatment.
Faculté des Sciences du Sport, Université Montpellier 1, INRA, UMR866, Dynamique Musculaire et Métabolisme, 2 Place Viala, 34060, Montpellier, France. anthony.sanchez@univ-montp1.fr
Anthony M J
AM
Sanchez
Katia
K
Collomp
Juliette
J
Carra
Fabio
F
Borrani
Olivier
O
Coste
Christian
C
Préfaut
Robin
R
Candau
D000054:Acceleration; D000284:Administration, Oral; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000494:pharmacology*; D001249:Asthma / Q000503:physiopathology; D056352:Athletes; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D015444:Exercise / Q000502:physiology; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D053580:Muscle Strength / Q000187:drug effects* / Q000502:physiology; D010919:Placebos; D013997:Time Factors; D055815:Young Adult
D001993:Bronchodilator Agents; D010919:Placebos; D000420:Albuterol